Eupraxia Pharmaceuticals's total assets for Q3 2024 were C$10.36M, a decrease of -69.67% from the previous quarter. EPRX total liabilities were C$2.39M for the fiscal quarter, a -85.01% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.